- Home
- GPRK vs OCGN Comparison
GPRK vs OCGN Comparison
Compare GPRK & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRK | OCGN |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.8M | 387.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GPRK | OCGN |
|---|---|---|
| Price | $7.10 | $1.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $8.50 | $7.00 |
| AVG Volume (30 Days) | 724.8K | ★ 3.4M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $525,938,000.00 | $5,370,000.00 |
| Revenue This Year | N/A | $32.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.82 | ★ N/A |
| Revenue Growth | N/A | ★ 14.26 |
| 52 Week Low | $5.66 | $0.52 |
| 52 Week High | $11.67 | $1.90 |
Technical Indicators
Market Signals| Indicator | GPRK | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.30 | 61.79 |
| Support Level | $6.97 | $1.35 |
| Resistance Level | $7.33 | $1.26 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | -0.15 | 0.04 |
| Stochastic Oscillator | 7.23 | 78.43 |
Price Performance
Historical ComparisonAbout GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").